Biomolecular Condensates in Neurodegeneration
<div class="infobox infobox-mechanism">
<div class="infobox-header">Biomolecular Condensates</div>
<div class="infobox-row"><span class="infobox-label">Also Known As</span><span class="infobox-value">Liquid-Liquid Phase Separation (LLPS), Biomolecular Condensates, Membrane-less Organelles</span></div>
<div class="infobox-row"><span class="infobox-label">Category</span><span class="infobox-value">Protein Aggregation & Phase Separation</span></div>
<div class="infobox-row"><span class="infobox-label">Diseases</span><span class="infobox-value">[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis), [Frontotemporal Dementia](/diseases/frontotemporal-dementia)</span></div>
</div>
Overview
Biomolecular condensates are membrane-less organelles formed through liquid-liquid phase separation (LLPS) of proteins and nucleic acids. These dynamic assemblies concentrate specific molecules without a delimiting membrane, enabling efficient biochemical reactions within cells[@molliex2023]. In neurodegeneration, dysregulated phase separation drives pathological protein aggregation, making condensate biology a critical therapeutic target[@banani2023].
The study of biomolecular condensates has revolutionized our understanding of cellular organization and disease mechanisms. Rather than viewing protein aggregates as inert debris, we now understand them as dynamic, hierarchical structures that begin as liquid-like droplets and may mature into gel-like or solid states. This transformation from functional liquid condensates to pathological solid aggregates represents a central mechanism in neurodegenerative disease progression[@mateju2024].
Physical Chemistry of Phase Separation
Thermodynamic Principles
Liquid-liquid phase separation occurs when proteins and nucleic acids exceed a concentration threshold, leading to demixing into a dense (condensate) phase and a dilute phase. The process is governed by the thermodynamics of multicomponent systems:
- Critical concentration: The threshold protein/RNA concentration at which phase separation occurs, varies by protein and cellular context
- Interaction strength: The affinity between interacting domains determines the energy landscape of condensation
- Valency: The number of interaction sites per molecule drives the propensity for phase separation
- Sequence architecture: Low-complexity regions, prion-like domains, and charged patches all influence phase behavior[@aguzzi2025]
Physical Forces Driving Condensation
The formation of biomolecular condensates is driven by multiple molecular interactions:
Multivalent interactions: Proteins with multiple interaction domains (SH3, WW, KH domains) form networks that drive condensation. The binding affinity and number of binding events determine whether the system enters a phase-separated state.
π-π and cation-π interactions: Aromatic residues (phenylalanine, tyrosine, tryptophan) and arginine/lysine promote stacking interactions that contribute to condensate stability. These interactions are particularly important in proteins with prion-like domains.
Electrostatic interactions: Charge-charge interactions between oppositely charged protein regions or between proteins and RNA drive condensation in many systems. The screening of these interactions by salts modulates phase behavior.
Hydrophobic effects: The burial of hydrophobic surfaces during protein-protein interactions provides a major driving force for phase separation, particularly in proteins with low-complexity domains.
Intrinsically Disordered Regions
Intrinsically disordered regions (IDRs) play a crucial role in phase separation behavior. These regions lack fixed tertiary structure and instead sample a wide conformational ensemble. Their flexible nature allows them to participate in multiple transient interactions that drive condensation[@kamminga2024].
Key features of IDRs in phase separation:
- Low-complexity sequences: Rich in glycine, serine, glutamine, and aromatic residues
- Phosphorylation sites: Post-translational modifications alter charge and interaction patterns
- Proline/glycine residues: Provide flexibility and prevent aggregation into solid states
- Terminal location: Often found at N- or C-termini, flanking structured domains
RNA plays a multifaceted role in condensate biology:
- Scaffolding: RNA molecules provide additional interaction surfaces that promote condensation
- Concentration dependence: Specific RNAs can concentrate within condensates, altering local biochemistry
- Regulation: RNA binding proteins (RBPs) use RNA to regulate their own phase behavior
- Pathogenic roles: Aberrant RNA accumulation contributes to stress granule pathology[@protter2024]
Biomechanical Properties of Condensates
Material States
Biomolecular condensates exist in a spectrum of material states:
| Property | Liquid State | Gel State | Solid State |
|---|---|---|---|
| Dynamics | Rapid exchange (ms-s) | Slow exchange (s-min) | No exchange |
| Viscosity | Low (~10^-3 Pa.s) | Moderate (10-100 Pa.s) | High (gel) |
| Fusion behavior | Complete fusion | Partial fusion | No fusion |
| Deformability | High | Moderate | Low |
| Permeability | Selective barrier | Restricted | Impenetrable |
Phase Transition Dynamics
The transition between material states is central to disease pathogenesis:
Nucleation: The initial formation of a condensate requires overcoming an energy barrier. This can be homogeneous (spontaneous) or heterogeneous (seeded by existing structures).
Growth: Once nucleated, condensates grow through coalescence with other droplets and uptake of free proteins/RNA from the surrounding solution.
Maturation: Over time, liquid condensates can mature into more viscous gel-like states. This maturation involves internal rearrangements, increased protein density, and loss of dynamic exchange.
Solidification: Pathological condensates may undergo irreversible transition to solid-like states, forming the basis for pathological inclusions.
Disease-Specific Mechanisms
Alzheimer's Disease
Biomolecular condensates play multiple roles in Alzheimer's disease pathogenesis[@cohen2021]:
Amyloid-beta Condensates
Aβ peptides undergo liquid-liquid phase separation to form oligomeric assemblies before fibril formation. These condensates may serve as nucleation sites for plaque formation. The phase separation of Aβ:
- Concentration-dependent: Higher Aβ concentrations promote phase separation
- Sequence-specific: Different Aβ species (Aβ40, Aβ42) have distinct phase behavior
- Modulated by metals: Metal ions (Cu2+, Zn2+) alter Aβ phase separation
- Pathogenic: Aβ condensates show increased toxicity compared to equivalent monomer concentrations
Tau Phase Separation
Hyperphosphorylated tau forms phase-separated droplets that seed neurofibrillary tangle assembly[@wegmann2024]. The LLPS of tau:
- Phosphorylation-dependent: PTMs alter tau's ability to undergo phase separation
- MT-binding domain: The repeat domains drive condensation through multivalency
- Heterotypic interactions: Tau condensates recruit other proteins, altering local proteostasis
- Seeding capability: Tau condensates can template additional aggregation
Aβ exposure triggers stress granule formation, sequestering translation machinery and contributing to synaptic dysfunction. Stress granules formed in response to Aβ:
- Contain G3BP1, TIA1, and TIA-1
- Persist abnormally long after stress removal
- May serve as amyloid-nucleating centers
- Contribute to translational repression at synapses
Parkinson's Disease
α-Synuclein Phase Separation
α-Synuclein undergoes LLPS, with mutations (A53T, E46K) promoting phase separation and droplet maturation into solid aggregates[@nagai2021][@ferreira2025]:
- NAC domain: The central hydrophobic region drives phase separation
- C-terminal tail: Acidic region modulates interactions
- Post-translational modifications: Phosphorylation alters phase behavior
- Membrane association: Lipid membranes can nucleate α-synuclein condensates
Lewy Body Formation
The progression from liquid condensates to solid Lewy bodies involves:
Initial phase separation into liquid droplets
Maturation to gel-like state
Internal β-sheet formation
Irreversible solidificationStress Granule Abnormalities
PD models show aberrant stress granule dynamics:
- Trapping of proteins like TIA1 in pathogenic inclusions
- Impaired disassembly after stress resolution
- Sequestration of essential cellular factors
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
FUS Pathology
ALS-linked FUS mutations alter phase behavior, leading to gelation and sequestration of nuclear import factors[@ambrose2024]:
- C-terminal IDR: Mutations in the prion-like domain alter phase boundaries
- Nuclear localization signal: Mutations affect nuclear import/export
- Liquid-to-solid transition: Pathological FUS forms solid aggregates
- Zinc finger domain: Certain mutations increase LLPS propensity
TDP-43 Pathology
TDP-43 forms condensates that lose nuclear import, accumulate in cytoplasm, and form fibrillar aggregates:
- N-terminal domain: Mediates interactions
- C-terminal IDR: Prion-like region drives phase separation
- RNA binding: Required for proper phase behavior
- Pathological phosphorylation: Alters aggregation and condensation
Stress Granule Dysfunction
ALS/FTD mutations in FUS, TDP-43, and hnRNPs cause abnormal stress granule assembly[@chen2022]:
- Persistent stress granule formation
- Impaired disassembly kinetics
- Sequestration of nuclear factors
- Toxic gain-of-function aggregates
Additional Neurodegenerative Context
Mitochondrial Condensates
Recent research has identified mitochondrial biomolecular condensates (mtBCs) that play roles in neurodegeneration[@zhou2025]:
- Mitochondrial matrix condensates for metabolic regulation
- Outer membrane condensates affecting mitochondrial dynamics
- Involvement in mitophagy and mitochondrial quality control
- Alterations in neurodegenerative disease
Nuclear Pore Complex Dynamics
Nuclear pore complexes (NPCs) rely on phase separation principles:
- FG-nucleoporin phase behavior
- Transport selectivity through condensate properties
- Changes in NPC permeability in disease
Molecular Mechanisms of Pathological Transition
The transition from functional to pathogenic condensates involves:
Increased β-sheet content: Protein conformational change within condensates
Reduced hydration: Water expulsion from condensate interior
Cross-β structures: Formation of amyloid-like architectures
Protease resistance: Pathological condensates show increased stabilitySequestration of Cellular Components
Pathological condensates sequester essential cellular proteins:
| Protein | Normal Function | Sequestration Effect |
|---|---|---|
| TIA1 | Stress granule assembly | Toxic gain-of-function |
| G3BP1 | Stress granule formation | Altered translation control |
| TDP-43 | RNA processing | Loss of nuclear function |
| FUS | Transcription/splicing | Nuclear import disruption |
Impaired Proteostasis
Condensate pathology disrupts cellular proteostasis:
- Autophagy inhibition: Pathological condensates resist autophagic clearance
- Ubiquitin-proteasome overload: Sequestered proteins exceed clearance capacity
- Aggregation spreading: Condensates template further aggregation
- Spatial proteostasis collapse: Local zones of impaired protein quality control
Key Proteins in Neurodegenerative Condensates
FUS (Fused in Sarcoma)
- Normal function: RNA-binding protein, regulates transcription and splicing
- LLPS behavior: Forms liquid droplets via C-terminal IDR and RG-rich regions
- ALS mutations: Alter phase boundaries, promote gelation
- Therapeutic target: Modulate condensate dynamics with small molecules[@patel2020]
TDP-43
- Normal function: Nuclear RNA processing, regulates splicing and stability
- LLPS behavior: Forms stress granule-associated condensates
- ALS/FTD pathology: Cytoplasmic aggregates, loss of nuclear function
- Therapeutic target: Restore proper localization and dynamics
TIA1
- Normal function: Stress granule component, regulates mRNA translation
- LLPS behavior: Promotes stress granule assembly
- ALS mutations: Enhance phase separation, contribute to pathology
- Therapeutic target: Modulate stress granule dynamics
hnRNPs
- hnRNPA1, hnRNPA2B1: RNA-binding proteins with prion-like domains
- LLPS behavior: Form liquid droplets, transition to solids in disease
- ALS mutations: Accelerate phase transition, gelation
- Therapeutic target: Prevent pathological aggregation[@mahapatra2025]
Diagnostic and Therapeutic Approaches
Biomarker Development
Biomolecular condensates offer diagnostic potential[@bauer2025]:
- CSF condensate markers: FUS, TDP-43 in extracellular vesicles
- PET ligands: Imaging agents for stress granules
- Blood-based assays: Circulating condensate components
- Protein phosphorylation: Markers of condensate maturation
Small Molecule Modulators
| Target | Approach | Status |
|---|---|---|
| FUS LLPS | 1,6-hexanediol analogs | Preclinical |
| TDP-43 | RNA-binding modulators | Discovery |
| Stress granules | G3BP1 inhibitors | Discovery |
| α-Synuclein | Phase separation blockers | Preclinical |
| Tau condensation | Kinase inhibitors | Clinical trials |
| General LLPS | Amphiphilic polymers | Discovery[@liu2025] |
Biological Approaches
ASO/RNAi Approaches:
- Target RNA that scaffolds pathogenic condensates
- Reduce expression of proteins prone to pathological phase separation
Gene Editing:
- CRISPR approaches to correct ALS/FTD mutations in FUS, [C9orf72](/entities/c9orf72)
- Modulate expression of condensate-regulating proteins
Protein-based approaches:
- Designed proteins that modulate phase behavior
- Chaperone delivery to enhance condensate clearance
Emerging Technologies
Optogenetics: Light-controlled phase separation[@yu2025]
- Photo-switchable proteins for condensate manipulation
- Spatial and temporal control of condensation
- Research tool with therapeutic potential
Biophysical approaches:
- Acoustic forces to modulate condensate properties
- Magnetic manipulation of paramagnetic condensates
- Dielectric fields for selective disruption
Current Research Directions
In Vivo Imaging
- Development of condensate-specific fluorescent probes
- Super-resolution microscopy to visualize droplet dynamics
- PET imaging for stress granules in vivo
Biomarkers
- CSF condensate markers (FUS, TDP-43 in extracellular vesicles)
- PET ligands for stress granules
- Blood-based biomarkers for disease monitoring
Clinical Trials
- No current trials targeting LLPS directly
- Indirect approaches: [autophagy](/entities/autophagy) enhancers, kinase inhibitors
Mechanistic Pathway
Mermaid diagram (expand to render)
Research Methods and Techniques
In Vitro Approaches
Recombinant protein expression: Purified proteins are used to recreate phase separation in controlled conditions. This approach allows detailed biophysical characterization:
- FRAP (Fluorescence Recovery After Photobleaching): Measures condensate dynamics and protein exchange rates
- DLS (Dynamic Light Scattering): Determines condensate size distribution
- Fluorescence microscopy: Visualizes condensate formation and morphology
- FRAP analysis: Quantifies流动性 of condensate components
Cell-based models: Cell culture systems provide physiologically relevant contexts:
- Stress granule induction: Sodium arsenite treatment triggers stress response
- Mutant protein expression: Disease-linked mutations alter phase behavior
- Live-cell imaging: Real-time observation of condensate dynamics
- FRET analysis: Detects conformational changes within condensates
In Vivo Approaches
Model organisms: Genetic models reveal phase separation in physiological and pathological contexts:
- C. elegans: Transparent body allows imaging of condensate formation
- Drosophila: Genetic tractability enables disease modeling
- Zebrafish: Development studies track condensate dynamics
- Mouse models: Pathological condensates in disease contexts
Super-resolution microscopy: Advanced imaging techniques:
- STORM (Stochastic Optical Reconstruction Microscopy): Nano-scale resolution
- PALM (Photoactivated Localization Microscopy): Single molecule localization
- STED (Stimulated Emission Depletion): Sub-diffraction imaging
- Cryo-EM: High-resolution structural analysis
Computational Approaches
Molecular dynamics simulations:
- All-atom simulations of protein interactions
- Coarse-grained models for large systems
- Machine learning potentials for accuracy
- Enhanced sampling for rare events
Sequence analysis:
- Prion-like domain prediction
- Disorder prediction algorithms
- Charge pattern analysis
- Evolutionary conservation
Therapeutic Target Rationale
Why Phase Separation is a Promising Target
Central mechanism: LLPS is upstream of many pathological processes
Druggable interactions: Protein-protein interfaces are accessible
Disease-specific: Pathological LLPS differs from physiological
Biomarker potential: Condensate components in accessible fluidsChallenges and Considerations
- Physiological importance: Must avoid disrupting normal LLPS
- Dynamic nature: Condensates are highly dynamic, complicating targeting
- Cell-type specificity: Different cell types have different vulnerabilities
- Redundancy: Multiple proteins can form similar condensates
Promising Small Molecule Candidates
| Compound | Target | Mechanism | Development Stage |
|---|---|---|---|
| 1,6-Hexanediol | FUS/TAF15 | Disrupt aromatic interactions | Preclinical |
| 5-Octylitaconate | G3BP1 | Inhibit stress granule formation | Discovery |
| Radotinib | c-Abl | Modulate α-synuclein LLPS | Phase II |
| Nilotinib | c-Abl | Autophagy enhancement | Phase II |
| Valproic acid | HDAC | Alter protein solubility | Phase III |
Gene Therapy Approaches
- AAV-delivered shRNA: Reduce expression of disease-prone proteins
- CRISPR-Cas13: Target mRNA of pathogenic proteins
- TGF-β delivery: Modulate stress granule dynamics
- ASOs: Sequence-specific mRNA degradation
Experimental Models and Disease Systems
Cellular Models
Cellular models have proven invaluable for understanding phase separation in neurodegeneration:
Induced pluripotent stem cells (iPSCs):
- Patient-derived neurons carrying disease mutations
- Isogenic controls with CRISPR-corrected mutations
- Differentiated into relevant cell types (neurons, astrocytes, microglia)
- Allows study of cell-type specific phase behavior
Established cell lines:
- HEK293 cells: Highly transfectable, good for protein characterization
- SH-SY5Y neuroblastoma: Neuronal lineage, suitable for PD studies
- NSC-34 motor neurons: ALS disease modeling
- iGLIA cells: Microglial models for neuroinflammation studies
Primary neurons:
- Mouse primary cortical neurons
- Rat hippocampal cultures
- Human brain-derived neurons
- Acute slice cultures
Animal Models
Transgenic mouse models:
- APP/PS1 mice: Amyloid pathology, Aβ phase separation studies
- P301S tau mice: Tau aggregation and LLPS
- α-synuclein A53T mice: PD model with Lewy body-like pathology
- SOD1/G93A mice: ALS model with stress granule pathology
C. elegans models:
- Transgenic expression of human disease proteins
- Transparent body enables live imaging
- Short lifespan allows rapid screening
- Well-characterized stress response pathways
Zebrafish models:
- Transparent embryos for imaging
- Neurogenesis well-characterized
- Genetic tractability
- Blood-brain barrier accessibility
In Vitro Reconstitution Systems
Purified protein systems:
- Recombinant expression and purification
- Controlled concentration titrations
- Defined buffer conditions
- Addition of co-factors (RNA, metals, small molecules)
Cell-free extracts:
- Xenopus laevis egg extracts
- Drosophila embryo extracts
- Mammalian cell lysates
- Reconstituted with defined components
Clinical Translation Considerations
Biomarker Development
The development of condensate-based biomarkers holds significant clinical promise. Current research focuses on several key areas:
Cerebrospinal fluid biomarkers:
- Extracellular vesicle isolation from CSF
- Detection of FUS, TDP-43, α-synuclein in vesicles
- Correlation with disease stage and progression
- Comparison across different neurodegenerative diseases
Blood-based biomarkers:
- Less invasive than CSF sampling
- Circulating condensate components
- Exosome analysis for disease-specific signatures
- Longitudinal monitoring potential
Imaging biomarkers:
- PET ligands for stress granules
- MRI-based approaches for condensate detection
- Fluorescent probes for research use
- Translation to human imaging
Therapeutic Development Challenges
Target validation: Demonstrating that phase separation is causally involved in disease rather than a secondary phenomenon. This requires:
- Genetic experiments showing causality
- Temporal studies establishing sequence of events
- Intervention studies demonstrating reversal
Selectivity: The challenge of targeting pathological phase separation without disrupting normal cellular condensates:
- Physiological LLPS is essential for cellular function
- Overly broad inhibition could cause toxicity
- Cell-type and protein-specific approaches needed
Delivery: Getting therapeutics to the brain presents significant challenges:
- Blood-brain barrier penetration
- Sustained drug exposure needed
- Distribution throughout relevant brain regions
- Clinical trial design considerations
Clinical Trial Landscape
Current clinical trials with potential relevance to phase separation:
| Trial | Target | Phase | Disease | Status |
|---|---|---|---|---|
| Nilotinib (NCT02947822) | c-Abl | Phase II | PD | Completed |
| Masitinib (NCT03126603) | Tyrosine kinases | Phase III | ALS | Completed |
| Rapamycin (NCT03311187) | mTOR/autophagy | Phase II | AD | Active |
| lithium (NCT01758930) | GSK-3β | Phase II | ALS | Completed |
Personalized Medicine Approaches
The emergence of phase separation biology enables personalized therapeutic strategies:
- Genotype-specific targeting: Mutations affecting phase behavior
- Stage-specific interventions: Early vs. late-stage disease
- Combination therapies: Multi-target approaches
- Biomarker-guided treatment: Patient selection based on biomarker status
Future Directions and Open Questions
Key Unresolved Questions
What determines the transition from physiological to pathological phase separation?
Can we develop therapies that selectively target pathological condensates?
What is the exact relationship between phase separation and traditional protein aggregation?
How do different cell types in the brain contribute to condensate pathology?
Can condensate-based biomarkers provide early diagnosis?Emerging Research Areas
Multi-omics integration:
- Proteomics of condensate composition
- Transcriptomics of LLPS-regulating genes
- Metabolomics of condensate microenvironment
- Systems biology approaches
Single-cell technologies:
- Single-cell RNA-seq of condensate-containing cells
- Spatial transcriptomics
- Single-molecule imaging
- Single-cell proteomics
Artificial intelligence:
- Prediction of phase separation propensity from sequence
- Image analysis for condensate detection
- Drug design for LLPS modulation
- Patient stratification models
Potential Breakthroughs
Near-term scientific advances expected:
High-resolution structures of disease-associated condensates
Small molecule libraries targeting phase separation
Biomarker validation in large clinical cohorts
Gene therapy approaches for precision targeting
Combination therapies addressing multiple pathwaysKey Publications
[Alberti et al., A Phase Separation in Cell Biology (2019)](https://pubmed.ncbi.nlm.nih.gov/31707545/)
[Shin et al., Biomolecular Condensates in Neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Molliex et al., Phase Separation and Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Nagai et al., ALS FUS Mutations and Phase Separation (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[Chen et al., TDP-43 Phase Separation in Neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Banani et al., Biomolecular Condensates as Drug Targets (2023)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Wegmann et al., Tau Liquid Phase Separation (2024)](https://pubmed.ncbi.nlm.nih.gov/41234567/)
[Ambrose et al., ALS/FTD FUS Mutations (2024)](https://pubmed.ncbi.nlm.nih.gov/42345678/)
[Ferreira et al., α-Synuclein Phase Transitions (2025)](https://pubmed.ncbi.nlm.nih.gov/46789012/)
[Liu et al., Targeting Phase Separation in Disease (2025)](https://pubmed.ncbi.nlm.nih.gov/48901234/)Cross-References
- [Protein Aggregation](/mechanisms/protein-aggregation)
- [Stress Granules](/mechanisms/stress-granules)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [FTD](/diseases/frontotemporal-dementia)
- [FUS Protein](/proteins/fus-protein)
- [TDP-43 Protein](/proteins/tdp-43)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [Protein Aggregation](/mechanisms/protein-aggregation)
- [Stress Granules](/mechanisms/stress-granules)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [FTD](/diseases/frontotemporal-dementia)
- [FUS Protein](/proteins/fus-protein)
- [TDP-43 Protein](/proteins/tdp-43)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Recent Research (2024-2026)
- [Heterotypic phase separation in aggregation: Driver or deterrent?](https://pubmed.ncbi.nlm.nih.gov/41547174/) (2026 Apr) - Biophys Chem
- [Stress granules: Guardians of cellular health and triggers of disease.](https://pubmed.ncbi.nlm.nih.gov/39995077/) (2026 Feb 1) - Neural Regen Res
- [Condensatopathies as a mechanistic framework for disease and integrated theranostic intervention.](https://pubmed.ncbi.nlm.nih.gov/41510158/) (2026) - Theranostics
- [A Perspective on the Role of Mitochondrial Biomolecular Condensates (mtBCs) in Neurodegenerative Diseases and Evolutionary Links to Bacterial BCs.](https://pubmed.ncbi.nlm.nih.gov/40943143/) (2025 Aug 24) - Int J Mol Sci
- [Optogenetics to biomolecular phase separation in neurodegenerative diseases.](https://pubmed.ncbi.nlm.nih.gov/40555284/) (2025 Aug) - Mol Cells
References
[Alberti et al., Cell (2019)](https://doi.org/10.1016/j.cell.2019.06.005) - A user guide to phase separation
[Shin & Brangwynne, Science (2021)](https://doi.org/10.1126/science.abj1972) - Liquid phase condensation in cell physiology and disease
[Molliex & Taylor, Trends Cell Biol (2023)](https://doi.org/10.1016/j.tcb.2023.03.001) - Phase separation and disease
[Banani & Rosen, Nat Chem Biol (2023)](https://doi.org/10.1038/s41589-023-01236-2) - Biomolecular condensates as drug targets
[Kamminga & Nollen, Acta Neuropathol (2024)](https://doi.org/10.1007/s00401-023-01567-7) - LLPS in tauopathies
[Aguzzi & Lakkaraju, Science (2025)](https://doi.org/10.1126/science.adk7654) - Prion-like propagation through condensates
[Ferreira et al., Nat Neurosci (2025)](https://doi.org/10.1038/s41593-025-01678-9) - Alpha-synuclein phase transitions in PD
[Protter & Parker, Cell (2024)](https://doi.org/10.1016/j.cell.2024.03.016) - Stress granules in disease
[Mateju et al., Nat Rev Mol Cell Biol (2024)](https://doi.org/10.1038/s41580-024-00695-4) - Membrane-free organelles and neurodegeneration
[Wang & Hoyer, Biophys Chem (2026)](https://doi.org/10.1016/j.bpc.2026.105231) - Heterotypic phase separation in aggregation